{
}
UBS has maintained its "Buy" rating for Novartis, setting a price target of 111 francs. Analyst Matthew Weston noted that the pharmaceutical company's new medium-term targets reflect strong confidence, significantly exceeding market consensus.
AstraZeneca Plc has shed its last bearish analyst ratings as UBS upgraded the stock to neutral, following a significant share-price decline of around 10% this month. The company now holds 24 buy ratings and seven holds, with no sell ratings, despite ongoing investigations in China impacting sentiment. Analysts from Nordea Bank and Intron Health have also raised their ratings, suggesting the recent slump in shares was overdone.
AstraZeneca Plc has shed its last bearish analyst ratings as UBS upgraded the stock to neutral, following a significant share-price decline of around 10% this month. The company now holds 24 buy ratings and seven holds, with no sells, despite ongoing investigations in China impacting sentiment. Analysts from Nordea Bank and Intron Health also raised their ratings, suggesting the recent slump was overdone.
UBS has upgraded Astrazeneca"s shares from "Sell" to "Neutral," maintaining a target price of 11,300 pence following a significant drop in the company"s stock. Analyst Matthew Weston notes considerable uncertainties in China but believes the pharmaceutical authority there will remain supportive of Astrazeneca. However, his earnings estimates, which are below consensus, limit a more favorable rating.
UBS has upgraded Astrazeneca"s shares from "Sell" to "Neutral," maintaining a price target of 11,300 pence after a recent decline in share price. Analyst Matthew Weston notes significant uncertainties in China, though the local pharmaceutical authority is expected to remain supportive of the company. However, below-consensus earnings estimates limit a more favorable rating.
UBS has upgraded Astrazeneca"s shares from "Sell" to "Neutral," maintaining a price target of 11,300 pence following a significant drop in share price. Analyst Matthew Weston notes considerable uncertainties in China but believes the pharmaceutical authority there will remain supportive of the company. However, below-consensus earnings estimates hinder a more favorable rating.
UBS has upgraded AstraZeneca"s shares from "Sell" to "Neutral," maintaining a target price of 11,300 pence following a significant drop in the company"s stock. Analyst Matthew Weston notes considerable uncertainties in China but believes the local pharmaceutical authority will remain supportive of AstraZeneca. His earnings estimates, which are below consensus, limit a more favorable rating for the shares.
UBS has upgraded AstraZeneca"s rating from "Sell" to "Neutral," maintaining a target price of 11,300 pence. Analyst Matthew Weston noted significant uncertainties in China but believes the pharmaceutical authority there will remain supportive of the company. However, below-consensus earnings estimates limit a more favorable outlook.
UBS has maintained a "Buy" rating for Merck KGaA, setting a target price of 190 euros after the recent quarterly figures, which showed few surprises. Despite a 1.1% drop in share price to EUR 144.90, the stock has risen 2.0% since the start of 2024, indicating potential for growth. The Q4 2024 balance sheet is anticipated on March 6, 2025.
UBS has maintained a 'Buy' rating for Merck KGaA, setting a target price of 190 euros following the company's quarterly figures. Analyst Matthew Weston noted that the results showed few surprises after the recent capital market day. Merck KGaA is a leading global pharmaceutical and chemical company, with diverse sales across various product families and regions.
Matthew Weston
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
UBS maintains buy rating for Novartis with price target of 111 francs
09:28 21.11.2024
AstraZeneca shares rebound as UBS upgrades stock to neutral rating
United States Dollar
Shell plc
Intron Health
AstraZeneca PLC
China National Medical Products Administration
Nordea Bank Abp
UBS Group AG
GBR
Joe Easton
Matthew Weston
Show more
12:05 20.11.2024
AstraZeneca stock upgraded as analysts shift from sell to neutral ratings
AstraZeneca PLC
Shell plc
China National Medical Products Administration
Nordea Bank Abp
UBS Group AG
GBR
Matthew Weston
Joe Easton
Show more
12:05 20.11.2024
UBS upgrades AstraZeneca to neutral amid uncertainties in China
09:35 20.11.2024
ubs upgrades astrazeneca to neutral with target price of 11300 pence
08:35 20.11.2024
ubs upgrades astrazeneca to neutral amid uncertainties in china
07:51 20.11.2024
ubs upgrades astrazeneca to neutral amid uncertainties in china
07:43 20.11.2024
ubs upgrades astrazeneca to neutral with target price of 11300 pence
06:51 20.11.2024
ubs maintains buy rating for merck with target price of 190 euros
11:37 15.11.2024
ubs maintains buy rating for merck kgaa with target price of 190 euros
11:33 15.11.2024
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Retail and Consumer Goods
Global Financial Events
Finance Mergers & Acquisitions
Global Trade Developments
Industry Mergers & Acquisitions
Central Bank Actions
CEO Changes
Banking Regulations
Supply Chain Management
Startups & Entrepreneurship
Energy Sector Developments
AI Innovations
Government Economic Policies
Workplace Trends
Cryptocurrency Trends
Market Analysis and Predictions
Emerging Startups
Countries:
Companies:
The Goldman Sachs Group, Inc.
Bank of America Corporation
Alphabet Inc.
Apple Inc.
Barclays PLC
Tesla, Inc.
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank RV Global PP
Commerzbank AG
Lloyds Banking Group plc
PepsiCo, Inc.
BNP Paribas SA
Google Inc.
NVIDIA Corporation
UBS Group AG
Wix.com Ltd.
BP Castrol K.K.
Valvoline Inc.
Bosch Limited
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Indian Rupee
Japanese Yen
Indonesian Rupiah
Canadian Dollar
Russian Ruble
South Korean Won
United Arab Emirates Dirham
Offshore Chinese Yuan
Ghanaian Cedi
Hungarian Forint
Albanian Lek
Brazilian Real
Singapore Dollar
Qatari Riyal
Jordanian Dinar
People:
Donald Trump
Elon Musk
Warren Buffett
Sergey Brin
Larry Page
Goldman Sachs
Kelvin Taylor
Carsten Fritsch
Christopher Chandler
Scott Bessent
Martin Schlegel
Jerome Powell
Kubra Khan
Joe Biden
Volkmar Baur
Christopher Wallerstedt
Brian Moynihan
Airlangga Hartarto
Francesco Gaetano Caltagirone
Leonardo Del Vecchio